GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients.
Mira T KeddisMatthew R HowardLeyton GalapiaErin F BarretoNan ZhangRichard J ButterfieldAndrew D RulePublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2023)
eGFRcr better represents the true relationship between GFR and outcomes after kidney transplantation because it has less non-GFR residual association. Cystatin C is better interpreted as a non-specific prognostic biomarker than as eGFR in the kidney transplant setting.